Skip header and navigation

9 records – page 1 of 1.

Cinacalcet (Sensipar) for secondary hyperparathyroidism in chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35371
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1465
Available Online
View Pamphlet
Secondary hyperparathyroidism is a condition that can be caused by chronic kidney disease (CKD). It happens when your kidneys cannot filter out waste products the right way. This leads to too much parathyroid hormone in your blood. Cinacalcet (sin-a-KAL-cet) is a medication that lowers the amount of parathyroid hormone in your blood. This will help to balance the amount of calcium and phosphorous in your blood. Sensipar® is the brand name for cinacalcet. This pamphlet explains how to take cinac…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Cinacalcet
Renal Insufficiency, Chronic - drug therapy
Hyperparathyroidism, Secondary - drug therapy
Subjects (LCSH)
Chronic renal failure
Hyperparathyroidism
Kidneys--Diseases--Treatment
Abstract
Secondary hyperparathyroidism is a condition that can be caused by chronic kidney disease (CKD). It happens when your kidneys cannot filter out waste products the right way. This leads to too much parathyroid hormone in your blood. Cinacalcet (sin-a-KAL-cet) is a medication that lowers the amount of parathyroid hormone in your blood. This will help to balance the amount of calcium and phosphorous in your blood. Sensipar® is the brand name for cinacalcet. This pamphlet explains how to take cinacalcet, possible side effects, and how to store this medication.
Notes
Previous title: Sensipar (Cinacalcet) to treat secondary hyperparathyroidism in chronic kidney disease
Previous title: Cinacalcet (Sensipar) to treat secondary hyperparathyroidism in chronic kidney disease (CKD)
Responsibility
Prepared by: Renal Program
Pamphlet Number
1465
Less detail

Dialysis patients : being prepared for an emergency

https://libcat.nshealth.ca/en/permalink/chpams35535
Nova Scotia Health Authority. Community Dialysis. Halifax, NS: Nova Scotia Health Authority , 2021.
Pamphlet Number
1564
Available Online
View Pamphlet
This pamphlet provides instructions on what dialysis patients should do if an emergency prevents them from starting or finishing their dialysis treatment at home or attending an appointment for dialysis. It explains what precautions to take, who to contact in an emergency, and what medications to take, and provides answers to common questions. The French version of this pamphlet 1901, "Patients recevant de la dialyse : se préparer en cas d’urgence", is also available.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Community Dialysis
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2021
Format
Pamphlet
Language
English
Physical Description
1 electronic document (6 p.) : digital, PDF file
Subjects (MeSH)
Kidney Diseases - therapy
Dialysis
Subjects (LCSH)
Kidneys--Diseases--Treatment
Dialysis
Abstract
This pamphlet provides instructions on what dialysis patients should do if an emergency prevents them from starting or finishing their dialysis treatment at home or attending an appointment for dialysis. It explains what precautions to take, who to contact in an emergency, and what medications to take, and provides answers to common questions. The French version of this pamphlet 1901, "Patients recevant de la dialyse : se préparer en cas d’urgence", is also available.
Responsibility
Prepared by: Community Dialysis
Pamphlet Number
1564
Less detail

Kidney Health Clinic : Yarmouth kidney care services

https://libcat.nshealth.ca/en/permalink/chpams36563
Nova Scotia Health Authority. Yarmouth Regional Hospital, Kidney Health Clinic. Halifax, NS: Nova Scotia Health Authority , 2019.
Pamphlet Number
1991
Available Online
View Pamphlet
The Kidney Health Clinic is for patients diagnosed with Chronic Kidney Disease (CKD). CKD means having kidney damage or a lower level of kidney function for 3 months or more. The goal of the Kidney Clinic is to stop or slow down the progression of kidney disease. This pamphlet lists the team members you will meet at the clinic and what to expect when you come to the clinic. Contact information is also provided.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Yarmouth Regional Hospital, Kidney Health Clinic
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2019
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([6] p.) : digital, PDF file
Subjects (MeSH)
Kidney Diseases - therapy
Subjects (LCSH)
Kidneys--Diseases--Treatment
Abstract
The Kidney Health Clinic is for patients diagnosed with Chronic Kidney Disease (CKD). CKD means having kidney damage or a lower level of kidney function for 3 months or more. The goal of the Kidney Clinic is to stop or slow down the progression of kidney disease. This pamphlet lists the team members you will meet at the clinic and what to expect when you come to the clinic. Contact information is also provided.
Responsibility
Prepared by: Kidney Health Clinic, Yarmouth Regional Hospital
Pamphlet Number
1991
Less detail

Lanthanum (Fosrenol) and chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35370
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1466
Available Online
View Pamphlet
Lanthanum (LAN-tha-num) is a medication used to lower the amount of phosphorus (a mineral that builds strong bones and teeth) in your blood. Lanthanum binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. A person with chronic kidney disease (CKD) is less able to remove phosphorus from their body. When there is too much phosphorus in your blood, it pushes calcium out of your bones. This makes your bones weaker. Hemodialysis can remove some of the extra …
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal Insufficiency, Chronic - drug therapy
Renal Dialysis
Lanthanum
Subjects (LCSH)
Chronic renal failure
Kidneys--Diseases--Treatment
Hemodialysis
Abstract
Lanthanum (LAN-tha-num) is a medication used to lower the amount of phosphorus (a mineral that builds strong bones and teeth) in your blood. Lanthanum binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. A person with chronic kidney disease (CKD) is less able to remove phosphorus from their body. When there is too much phosphorus in your blood, it pushes calcium out of your bones. This makes your bones weaker. Hemodialysis can remove some of the extra phosphorus, but you may need a medication like lanthanam to remove more. Fosrenol® is the brand name for lanthanum. This pamphlet explains how to take lanthanum, possible side effects, and how to store this medication.
Notes
Previous title: Fosrenol (Lanthanum) and hemodialysis
Responsibility
Prepared by: Renal Program
Pamphlet Number
1466
Less detail

One-Alpha® (alfacalcidol) and hemodialysis

https://libcat.nshealth.ca/en/permalink/chpams36672
Nova Scotia Health Authority. Pharmacy Services, Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1470
Available Online
View Pamphlet
One-Alpha® is a medication with the active ingredient alfacalcidol. This is a form of vitamin D. The liver changes alfacalcidol to calcitriol, which is a form of vitamin D that can be used by the body. Alfacalcidol helps your body control your calcium and phosphate levels. Calcium and phosphate are needed to build healthy bones. People get vitamin D from sunlight, and from eating oily fish and milk products. People with kidney disease cannot change enough vitamin D into calcitriol. This can ca…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Pharmacy Services
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal Insufficiency, Chronic - drug therapy
Renal Dialysis
Subjects (LCSH)
Chronic renal failure
Kidneys--Diseases--Treatment
Hemodialysis
Abstract
One-Alpha® is a medication with the active ingredient alfacalcidol. This is a form of vitamin D. The liver changes alfacalcidol to calcitriol, which is a form of vitamin D that can be used by the body. Alfacalcidol helps your body control your calcium and phosphate levels. Calcium and phosphate are needed to build healthy bones. People get vitamin D from sunlight, and from eating oily fish and milk products. People with kidney disease cannot change enough vitamin D into calcitriol. This can cause low calcium levels of in the blood and weaker bones. One-Alpha® raises the amount of vitamin D in your body that can be used. How to take the medication, side effects to watch for, and how to store it are reviewed. One-Alpha® is a brand name for alfacalcidol.
Responsibility
Prepared by: Renal Pharmacy Team, Renal Program
Pamphlet Number
1470
Less detail

Patients recevant de la dialyse : se préparer en cas d’urgence

https://libcat.nshealth.ca/en/permalink/chpams36461
Nova Scotia Health Authority. Community Dialysis. Halifax, NS: Nova Scotia Health Authority , 2021.
Pamphlet Number
1901
Available Online
View Pamphlet
La présente brochure fournit des instructions sur ce que devraient faire les personnes dialysées si une urgence les empêche de commencer ou de terminer leur traitement de dialyse à la maison ou de se rendre à un rendez-vous de dialyse. Elle explique les précautions à prendre, indique avec qui communiquer en cas d’urgence et précise les médicaments à prendre. Elle répond aussi à des questions fréquemment posées. ; This pamphlet is a French translation of "Dialysis Patients: Being Prepared for an…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Community Dialysis
Alternate Title
Dialysis patients : being prepared for an emergency
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2021
Format
Pamphlet
Language
French
Physical Description
1 electronic document (6 p.) : digital, PDF file
Subjects (MeSH)
Kidney Diseases - therapy
Dialysis
Subjects (LCSH)
Kidneys--Diseases--Treatment
Dialysis
Abstract
La présente brochure fournit des instructions sur ce que devraient faire les personnes dialysées si une urgence les empêche de commencer ou de terminer leur traitement de dialyse à la maison ou de se rendre à un rendez-vous de dialyse. Elle explique les précautions à prendre, indique avec qui communiquer en cas d’urgence et précise les médicaments à prendre. Elle répond aussi à des questions fréquemment posées.
This pamphlet is a French translation of "Dialysis Patients: Being Prepared for an Emergency" pamphlet 1564. This pamphlet provides instructions on what dialysis patients should do if an emergency prevents them from starting or finishing their dialysis treatment at home or attending an appointment for dialysis. It explains what precautions to take, who to contact in an emergency, and what medications to take, and provides answers to common questions.
Responsibility
Prepared by: Community Dialysis
Pamphlet Number
1901
Less detail

Rocaltrol® (calcitriol) and hemodialysis

https://libcat.nshealth.ca/en/permalink/chpams36671
Nova Scotia Health Authority. Pharmacy Services, Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1468
Available Online
View Pamphlet
Rocaltrol® is a medication with the active ingredient calcitriol. This is a form of vitamin D that can be used by the body. Calcitriol helps your body control your calcium and phosphate levels. Calcium and phosphate are needed to build healthy bones. People get vitamin D from sunlight, and from eating oily fish and milk products. People with kidney disease cannot change enough vitamin D into calcitriol. This can cause low calcium levels in the blood and weaker bones. Rocaltrol raises the amoun…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Pharmacy Services
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal Insufficiency, Chronic - drug therapy
Renal Dialysis
Calcitriol
Subjects (LCSH)
Chronic renal failure
Kidneys--Diseases--Treatment
Hemodialysis
Abstract
Rocaltrol® is a medication with the active ingredient calcitriol. This is a form of vitamin D that can be used by the body. Calcitriol helps your body control your calcium and phosphate levels. Calcium and phosphate are needed to build healthy bones. People get vitamin D from sunlight, and from eating oily fish and milk products. People with kidney disease cannot change enough vitamin D into calcitriol. This can cause low calcium levels in the blood and weaker bones. Rocaltrol raises the amount of vitamin D in your body that can be used. How to take the medication, side effects to watch for, and how to store it are reviewed. Rocaltrol® is a brand name for calcitriol.
Responsibility
Prepared by: Renal Pharmacy Team, Renal Program
Pamphlet Number
1468
Less detail

Sevelamer (Renagel) and chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35372
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1464
Available Online
View Pamphlet
Sevelamer (se-VEL-a-mer) is a medication that lowers the amount of phosphorus (a mineral that builds strong bones and teeth) in your blood. Sevelamer binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. A person with chronic kidney disease (CKD) is less able to remove phosphorus from their body. When there is too much phosphorus in your blood, it pushes calcium out of your bones. This makes your bones weaker. Hemodialysis can remove some of the extra ph…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Sevelamer
Renal Insufficiency, Chronic - drug therapy
Renal Dialysis
Subjects (LCSH)
Hemodialysis
Chronic renal failure
Kidneys--Diseases--Treatment
Abstract
Sevelamer (se-VEL-a-mer) is a medication that lowers the amount of phosphorus (a mineral that builds strong bones and teeth) in your blood. Sevelamer binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. A person with chronic kidney disease (CKD) is less able to remove phosphorus from their body. When there is too much phosphorus in your blood, it pushes calcium out of your bones. This makes your bones weaker. Hemodialysis can remove some of the extra phosphorus, but you may need a medication like sevelamer to remove more. Renagel® is one brand name for sevelamer. This pamphlet explains how to take sevelamer, possible side effects, and how to store this medication.
Notes
Previous title: Renagel (Sevelamer) and Hemodialysis
Responsibility
Prepared by: Renal Program
Pamphlet Number
1464
Less detail

Velphoro® (sucroferric oxyhydroxide) and chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams37620
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
2307
Available Online
View Pamphlet
Velphoro® is a medication used to treat high levels of phosphorous in the blood. Phosphorous is a mineral that builds strong bones and teeth. Velphoro® binds (attaches) to phosphorous from the foods you eat and stops your body from taking it in. This pamphlet explains why someone with with chronic kidney disease (CKD) needs to take this medication, how to take and store it, and possible side effects.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([2] p.) : digital, PDF file
Subjects (MeSH)
Kidney Diseases - drug therapy
Subjects (LCSH)
Kidneys--Diseases--Treatment
Specialty
Nephrology
Medications
Abstract
Velphoro® is a medication used to treat high levels of phosphorous in the blood. Phosphorous is a mineral that builds strong bones and teeth. Velphoro® binds (attaches) to phosphorous from the foods you eat and stops your body from taking it in. This pamphlet explains why someone with with chronic kidney disease (CKD) needs to take this medication, how to take and store it, and possible side effects.
Responsibility
Prepared by: Renal Program
Pamphlet Number
2307
Less detail

9 records – page 1 of 1.